HRP20210561T1 - Mjesta za vezanje antitijela specifičnih za egfrviii - Google Patents
Mjesta za vezanje antitijela specifičnih za egfrviii Download PDFInfo
- Publication number
- HRP20210561T1 HRP20210561T1 HRP20210561TT HRP20210561T HRP20210561T1 HR P20210561 T1 HRP20210561 T1 HR P20210561T1 HR P20210561T T HRP20210561T T HR P20210561TT HR P20210561 T HRP20210561 T HR P20210561T HR P20210561 T1 HRP20210561 T1 HR P20210561T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence according
- egfrviii
- Prior art date
Links
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 title claims 34
- 108010032595 Antibody Binding Sites Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 74
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 6
- 108091008324 binding proteins Proteins 0.000 claims 5
- 102000023732 binding proteins Human genes 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 3
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 claims 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (18)
1. EGFRvIII protein vezanja s najmanje jednim EGFRvIII mjestom vezanja sadrži domenu promjenjivog teškog lanca antitijela i domenu promjenjivog lakog lanca antitijela, i pri čemu
(a)
(a1) domena promjenljivog teškog lanca antitijela sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:27, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:28, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domena promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:30, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:31 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:32;
(a2) domena promjenjivog teškog lanca antitijela sadrže CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:33, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:28, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:34, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:31 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:35;
(a3) domenu promjenjivog teškog lanca antitijela sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:33, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:28, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:36, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:31 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:37;
(a4) domenu promjenjivog teškog lanca antitijela sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:33, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:38, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:39, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:40 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:41;
(a5) domenu promjenjivog teškog lanca antitijela sadrži CDR1 koji ima sekvencu aminokiseline sukladno SEK ID BR:42, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:43, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:44, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:40 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:45;
(a6) domenu promjenjivog teškog lanca antitijela sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:46, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:28, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:47, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:40 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:48;
(a7) domenu promjenjivog teškog lanca antitijela sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:49, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:50, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:51, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:40 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:52;
(a8) domenu promjenjivog teškog lanca antitijela sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:53, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:54, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:44, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:40 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:55;
(a9) domenu promjenjivog teškog lanca antitijela sadrži CDR1 koji ima sekvencu aminokiseline sukladno SEK ID BR:53, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:28, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:56, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:57 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:58;
(a10) domenu promjenjivog teškog lanca antitijela sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:46, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:28, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:59, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:40 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:60;
(a11) domenu promjenjivog teškog lanca antitijela sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR: 33, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR: 61, CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:44, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:40 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:62;
(a12) domenu promjenjivog teškog lanca antitijela sadrži CDR1 sa sekvencom aminokiseline sukladno YDFSSYWIG, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:63, CDR3 sa sekvencom aminokiseline SEK ID BR:29 i domenu promjenjivog lakog lanca antitijela koji sadrži CDR1 sa sekvencom aminokiseline sukladno SEK ID BR:64, CDR2 sa sekvencom aminokiseline sukladno SEK ID BR:31 i CDR3 sa sekvencom aminokiseline sukladno SEK ID BR:65;
pri čemu se EGFRvIII mjesto vezanja veže na EGFRvIII pozitivne stanice, ali se ne veže na EGFR pozitivne stanice u analizi protočne citometrije (FACS);
ili
(b) domenu promjenjivog teškog lanca antitijela je odabran sukladno skupine koja sadrži SEK ID BR:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25 i domenu promjenjivog lakog lanca antitijela je odabran sukladno skupine koja sadrži SEK ID BR: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 26.
2. EGFRvIII protein vezanja sukladno patentnom zahtjevu 1 sadrži domenu promjenjivog teškog lanca antitijela odabran sukladno skupine koja sadrži SEK ID BR:5, 7 i 25 ili domenu promjenjivog lakog lanca antitijela odabran sukladno skupini koja sadrži SEK ID BR: 6, 8 i 26.
3. EGFRvIII protein vezanja sukladno patentnom zahtjevu 1 ili 2, pri čemu najmanje 80% EGFRvIII molekula receptora prisutnih na neobrađenim stanicama je i dalje su dostupne nakon izlaganja tih satnica EGFRvIII vezivnom proteinu pri uvjetima saturacije tog vezivnog proteina na 37°C tokom 24 sata.
4. EGFRvIII protein vezanja sukladno bilo kojem od patentnih zahtjeva 1 do 3, pri čemu taj da protein sadrži najmanje jednu daljnju funkcionalnu domenu.
5. EGFRvIII protein vezanja sukladno patentnom zahtjevu 4, naznačen time što je najmanje jedna daljnja funkcionalna domena efektor domena.
6. EGFRvIII protein vezanja sukladno patentnom zahtjevu 5, pri čemu je domena efektora specifična za T- ili NK-stanice.
7. EGFRvIII protein vezanja sukladno patentnom zahtjevu 5 ili 6, pri čemu joj jedan domenu efektora jeste CD3 mesto vezanja koje sadrži najmanje jednu domenu promjenjivog teškog lanca antitijela i najmanje jedan domenu promjenjivog lakog lanca koja stvara mjesto vezanja antigena za CD3.
8. EGFRvIII protein vezanja sukladno patentnom zahtjevu 7, pri čemu to CD3 mjesto vezanja sadrži domenu promjenjivog teškog lanca sa sekvencom aminokisleine sukladno SEK ID BR: 23 i domenu promjenjivog lakog lanca sa sekvencom sukladno aminokiseline sukladno SEK ID BR: 24
9. EGFRvIII protein vezanja sukladno bilo kojem od patentnih zahtjeva 1 do 8, pri čemu je taj protein vezanja višestrukospecifičan.
10. EGFRvIII protein vezanja sukladno patentnom zahtjevu 9, pri čemu je protein vezanja trostrukospecifičan.
11. EGFRvIII protein vezanja sukladno bilo kojem od patentnih zahtjeva 1 do 10, pri čemu je taj protein vezanja dimerni protein.
12. EGFRvIII protein vezanja sukladno patentnom zahtjevu 11, pri čemu je protein vezanja tandem diatijelo specifično za EGFRvIII i CD3 (EGFRvIII/CD3) ili tandem diatijelo specifično za EGFRvIII i CD16A (EGFRvIII/CD16A).
13. EGFRvIII protein vezanja sukladno patentnog zahtjevu 12, pri čemu se u svakom polipeptidu četiri domena promjenjivog lanca spoje jedan s drugim uz pomoć peptidnih veznika L1, L2 i L3 sukladno redoslijedu:
(i) VL (CD3)-L1-VH (EGFRvIII)-L2-VL(EGFRvIII)-L3-VH(CD3); ili
(ii) VH (CD3)-L1-VL(EGFRvIII)-L2-VH(EGFRvIII)-L3-VL(CD3); ili
(iii) VL(EGFRvIII)-L1-VH(CD3)-L2-VL(CD3)-L3-VH(EGFRvIII); ili
(iv) VH(EGFRvIII)-L1-VL(CD3)-L2-VH(CD3)-L3-VL(EGFRvIII).
14. EGFRvIII protein vezanja sukladno patentnom zahtjevu 13, pri čemu se linkeri L1, L2 i L3 sastoje od 12 ostataka aminokiselina, ili manje.
15. Polinukleotid koji kodira EGFRvIII protein vezanja sukladno bilo kojem od patentnih zahtjeva 1 do 14.
16. Vektor koji sadrži polinukleotid sukladno patentnom zahtjevu 15.
17. Stanica domaćin je transformirana ili transficirana s vektorom sukladno patentnom zahtjevu 16.
18. Farmaceutski pripravak koja sadrži (i) EGFRvIII protein vezanja sukladno bilo kojem od patentnih zahtjeva 1 do 14, vektor sukladno patentnom zahtjevu 16 ili stanicu domaćina sukladno patentnom zahtjevu 17 i (ii) farmaceutski prihvatljiv nosač.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13179630 | 2013-08-07 | ||
| EP13189599 | 2013-10-21 | ||
| PCT/EP2014/002177 WO2015018527A1 (en) | 2013-08-07 | 2014-08-07 | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| EP14758087.2A EP3030581B1 (en) | 2013-08-07 | 2014-08-07 | Antibody binding sites specific for egfrviii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210561T1 true HRP20210561T1 (hr) | 2021-05-14 |
Family
ID=51453717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210561TT HRP20210561T1 (hr) | 2013-08-07 | 2021-04-08 | Mjesta za vezanje antitijela specifičnih za egfrviii |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10273309B2 (hr) |
| EP (1) | EP3030581B1 (hr) |
| JP (1) | JP6529498B2 (hr) |
| CN (1) | CN105555804B (hr) |
| AU (1) | AU2014304930B2 (hr) |
| CA (1) | CA2920173C (hr) |
| DK (1) | DK3030581T3 (hr) |
| HK (1) | HK1218552A1 (hr) |
| HR (1) | HRP20210561T1 (hr) |
| HU (1) | HUE054057T2 (hr) |
| LT (1) | LT3030581T (hr) |
| RU (1) | RU2696892C2 (hr) |
| SI (1) | SI3030581T1 (hr) |
| WO (1) | WO2015018527A1 (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6632984B2 (ja) | 2014-03-11 | 2020-01-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ＥＧＦＲｖＩＩＩ抗体およびその使用 |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| CA2968510C (en) * | 2014-11-25 | 2020-11-03 | Pharmabcine Inc. | Novel egfrviii antibody and composition comprising same |
| JP2018516248A (ja) | 2015-05-29 | 2018-06-21 | アンフィヴェナ セラピューティクス，インク． | 二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法 |
| CN108289950B (zh) * | 2015-06-09 | 2022-10-21 | 纪念斯隆凯特琳癌症中心 | 特异于人hla呈递的ebv潜伏膜蛋白2a肽的t细胞受体样抗体药剂 |
| WO2016204966A1 (en) * | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) * | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| ES2904593T3 (es) | 2016-01-21 | 2022-04-05 | Pfizer | Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos |
| TWI755547B (zh) | 2016-01-21 | 2022-02-21 | 美商輝瑞股份有限公司 | 靶向表皮生長因子受體變異體iii之嵌合型抗原受體 |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| CN107556386A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用 |
| AU2017306507B2 (en) | 2016-08-05 | 2020-05-14 | Y-Biologics Inc. | Antibody to programmed death-ligand 1 (PD-L1) and use thereof |
| US11248048B2 (en) | 2016-08-05 | 2022-02-15 | Y-Biologics Inc. | Antibody to programmed cell death 1 (PD-1) and use thereof |
| CN106501518A (zh) * | 2017-01-06 | 2017-03-15 | 北京弘润天源生物技术股份有限公司 | 一种检测EGFRvⅢ的免疫组化抗体试剂及检测方法 |
| AU2018228719B2 (en) * | 2017-02-28 | 2023-03-30 | Affimed Gmbh | Tandem diabody for CD16A-directed NK-cell engagement |
| CA3089287A1 (en) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
| CA3090464A1 (en) * | 2018-03-14 | 2019-09-19 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
| CN113621062A (zh) * | 2018-12-21 | 2021-11-09 | 豪夫迈·罗氏有限公司 | 与cd3结合的抗体 |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| WO2022159685A2 (en) * | 2021-01-22 | 2022-07-28 | Vanderbilt University | Sars-cov-2 coronavirus antibodies and uses thereof |
| WO2023287941A2 (en) * | 2021-07-16 | 2023-01-19 | Medical Guidance Systems, Llc | Anti-tax interacting protein-1 (tip1) binding molecules |
| CN116375868A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| AU2001239857B9 (en) * | 2000-02-25 | 2006-07-27 | Duke University | Anti-EGFRvIII SCFVS with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| EP1638606B1 (en) * | 2003-06-27 | 2016-01-06 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
-
2014
- 2014-08-07 CA CA2920173A patent/CA2920173C/en active Active
- 2014-08-07 RU RU2016106577A patent/RU2696892C2/ru active
- 2014-08-07 DK DK14758087.2T patent/DK3030581T3/da active
- 2014-08-07 WO PCT/EP2014/002177 patent/WO2015018527A1/en active Application Filing
- 2014-08-07 HU HUE14758087A patent/HUE054057T2/hu unknown
- 2014-08-07 SI SI201431808T patent/SI3030581T1/sl unknown
- 2014-08-07 JP JP2016532264A patent/JP6529498B2/ja active Active
- 2014-08-07 CN CN201480045405.5A patent/CN105555804B/zh active Active
- 2014-08-07 AU AU2014304930A patent/AU2014304930B2/en active Active
- 2014-08-07 EP EP14758087.2A patent/EP3030581B1/en active Active
- 2014-08-07 LT LTEP14758087.2T patent/LT3030581T/lt unknown
-
2016
- 2016-02-04 US US15/015,261 patent/US10273309B2/en active Active
- 2016-06-06 HK HK16106459.3A patent/HK1218552A1/zh unknown
-
2021
- 2021-04-08 HR HRP20210561TT patent/HRP20210561T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016002610A8 (pt) | 2018-01-23 |
| US20160152728A1 (en) | 2016-06-02 |
| HUE054057T2 (hu) | 2021-08-30 |
| SI3030581T1 (sl) | 2021-07-30 |
| JP2016536322A (ja) | 2016-11-24 |
| EP3030581A1 (en) | 2016-06-15 |
| WO2015018527A1 (en) | 2015-02-12 |
| EP3030581B1 (en) | 2021-01-20 |
| CA2920173A1 (en) | 2015-02-12 |
| AU2014304930A1 (en) | 2016-02-25 |
| US10273309B2 (en) | 2019-04-30 |
| BR112016002610A2 (pt) | 2017-09-12 |
| CN105555804A (zh) | 2016-05-04 |
| CN105555804B (zh) | 2020-12-25 |
| DK3030581T3 (da) | 2021-04-12 |
| LT3030581T (lt) | 2021-05-25 |
| RU2696892C2 (ru) | 2019-08-07 |
| JP6529498B2 (ja) | 2019-06-12 |
| RU2016106577A (ru) | 2017-09-14 |
| AU2014304930B2 (en) | 2019-11-21 |
| HK1218552A1 (zh) | 2017-02-24 |
| CA2920173C (en) | 2021-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210561T1 (hr) | Mjesta za vezanje antitijela specifičnih za egfrviii | |
| HRP20200679T1 (hr) | Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20170882T1 (hr) | Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse | |
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| HRP20201156T1 (hr) | Zajednički laki lanci i postupci primjene | |
| RS54423B1 (en) | ANTI-IGF ANTIBODIES | |
| JP2016536322A5 (hr) | ||
| JP2010535012A5 (hr) | ||
| HRP20140258T1 (hr) | Bispecifiäśni proteini koji se vežu na antigene | |
| HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
| JP2017529067A5 (hr) | ||
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| IL266893A (en) | Meditops and antibodies bind meditops and their use | |
| EA200800696A1 (ru) | Полипептиды и антитела | |
| HRP20140727T1 (hr) | Bivalentna, bispecifiäśna protutijela | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| HRP20220649T1 (hr) | Novi bispecifični format pogodan za upotrebu u visokopropusnom skriningu | |
| JP2015508757A5 (hr) | ||
| CL2010000096A1 (es) | Anticuerpo monoclonal o una porción que se une al antígeno del mismo que se une a alk-1, molécula de acido nucleico codificante; composición farmaceutica que lo comprende; uso de dicho anticuerpo para preparar un medicamento útil para inhibir la angiogénesis en un mamifero. (div.sol.2333-06). | |
| RU2020129387A (ru) | Антитела к pd-1 собак | |
| RU2013110876A (ru) | Активируемые биспецифические антитела | |
| HRP20161548T1 (hr) | Protutijela za il-25 | |
| CO6280541A2 (es) | Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40 |